Renal carcinomas associated with Xp1 1.2 translocation/TFE3 gene fusions: report of 18 cases

蔡海,陈少豪,许宁,郑清水,黄金杯,薛学义
DOI: https://doi.org/10.3760/cma.j.issn.1673-4416.2016.05.013
2016-01-01
Abstract:Objectives To investigate the treatments and research progress of renal carcinomas associated with Xp11.2 translocation/ TFE3 gene fusions.Methods From January 2009 to June 2015,18 cases of Xp11.2 translocation renal cell cancer (RCC) were treated in our hospital.Clinical manifestations,characteristics of RCC and surgical treatments were retrospectively analyzed.Results Most of the patients were under 45 years old.All of RCC were unilateral.Nephron sparing surgery or radical nephrectomy was performed according to the tumor size and the location.All patients had not complication of operation,postoperative reactions.Postoperative follow-up time was 6 ~ 80 months.2 cases with lung metastases postoperatively,1 case with death after 35 months happened.Conclusions Xp1 1.2 translocation kidney cancer occurs in young patients,is a kind of new classificational independently subtype of kidney cancer,which has a unique genetic type,high malignant degree.The surgical treatment is the first choice for the disease.
What problem does this paper attempt to address?